Active substances
Fluticasone + Formoterol
- SFDA 3
- NHS prices 3
- WHO EML 1
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| FLUTIFORM 125/5 mcg pressurised inhalation suspension | 0.125,0.005 mg,mg | Pressurised inhalation, suspension · Inhalation use | 1 Inhaler | SAR 130.00 | NCE · Prescription | Napp pharmacuticals limited UK | Valid |
| FLUTIFORM 250/10 mcg pressurised inhalation suspension | 0.25,0.01 mg,mg | Pressurised inhalation, suspension · Inhalation use | 1 Inhaler | SAR 225.00 | NCE · Prescription | Napp pharmacuticals limited UK | Valid |
| FLUTIFORM 50/5 mcg pressurised inhalation suspension | 0.05,0.005 mg,mg | Pressurised inhalation, suspension · Inhalation use | 1 Inhaler | SAR 105.00 | NCE · Prescription | Napp pharmacuticals limited UK | Valid |
Indications — CHI Daman Drug Formulary
ASTHMA
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| NHS Drug Tariff | Fluticasone 125micrograms/dose / Formoterol 5micrograms/dose inhaler CFC free | £28.00 | 120 dose | 1 Oct 2026 |
| NHS Drug Tariff | Fluticasone 250micrograms/dose / Formoterol 10micrograms/dose inhaler CFC free | £45.56 | 120 dose | 1 Oct 2026 |
| NHS Drug Tariff | Fluticasone 50micrograms/dose / Formoterol 5micrograms/dose inhaler CFC free | £14.40 | 120 dose | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 25.1. Antiasthmatic and medicines for chronic obstructive pulmonary disease · core
Therapeutic equivalent to budesonide + formoterol for Asthma
Components
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.